[Colchicine-Phoenix from the ashes].
Level 5 - mechanism / opinion, no new human data
Narrative review summarizing clinical uses and guideline updates without systematic review methodology
PubMed 39912853 · doi:10.1007/s00508-024-02490-7
What was done
This narrative review summarizes the efficacy, safety profile, traditional therapeutic roles, and emerging indications for colchicine based on recent clinical studies, FDA approvals, and guideline updates.
What was found
The abstract reports no quantitative numerical data or effect sizes. It describes colchicine's standard indications (gout acute care and prophylaxis, familial Mediterranean fever, pericarditis, neutrophilic dermatoses, Behçet's disease, and refractory oral aphthous ulcers). It highlights that the US FDA recently approved colchicine for cardiovascular risk reduction (myocardial infarction, stroke, revascularization, and cardiovascular death) in patients with atherosclerotic disease or multiple cardiovascular risk factors. It also notes an upgrade in cardiovascular prophylaxis recommendation from class IIb to IIa in the 2024 European Society of Cardiology guidelines, alongside demonstrated activity in acute coronary syndrome and atrial fibrillation.
Why it matters
Colchicine is transitioning from a traditional rheumatologic and autoinflammatory drug into a guideline-supported anti-inflammatory therapy for atherosclerotic cardiovascular disease.
Limits
The abstract provides no quantitative outcome figures, risk ratios, or adverse event rates. As a narrative review, it lacks a described systematic literature search methodology, predefined inclusion criteria, and formal risk-of-bias assessment.
Cited by
- supports Colchicine was utilized approximately 3,000 years ago in Egypt for reducing gout.